CR20190239A - Inhibidores de la magl - Google Patents
Inhibidores de la maglInfo
- Publication number
- CR20190239A CR20190239A CR20190239A CR20190239A CR20190239A CR 20190239 A CR20190239 A CR 20190239A CR 20190239 A CR20190239 A CR 20190239A CR 20190239 A CR20190239 A CR 20190239A CR 20190239 A CR20190239 A CR 20190239A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- compositions
- useful
- magl
- magl inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 102100029814 Monoglyceride lipase Human genes 0.000 abstract 2
- 101710116393 Monoglyceride lipase Proteins 0.000 abstract 2
- -1 bicyclic carbamates Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423102P | 2016-11-16 | 2016-11-16 | |
| PCT/US2017/061870 WO2018093949A1 (en) | 2016-11-16 | 2017-11-15 | Magl inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190239A true CR20190239A (es) | 2019-06-26 |
Family
ID=62145825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190239A CR20190239A (es) | 2016-11-16 | 2017-11-15 | Inhibidores de la magl |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11059822B2 (enExample) |
| EP (1) | EP3541820B1 (enExample) |
| JP (1) | JP7042468B2 (enExample) |
| KR (1) | KR20190080935A (enExample) |
| CN (1) | CN110267962B (enExample) |
| AU (1) | AU2017361253B2 (enExample) |
| BR (1) | BR112019009880A2 (enExample) |
| CA (1) | CA3043617A1 (enExample) |
| CL (1) | CL2019001336A1 (enExample) |
| CO (1) | CO2019004945A2 (enExample) |
| CR (1) | CR20190239A (enExample) |
| DO (1) | DOP2019000118A (enExample) |
| EA (1) | EA038150B1 (enExample) |
| EC (1) | ECSP19034535A (enExample) |
| ES (1) | ES2952582T3 (enExample) |
| IL (1) | IL266547B (enExample) |
| JO (1) | JOP20190107A1 (enExample) |
| MA (1) | MA46855A (enExample) |
| MX (1) | MX389627B (enExample) |
| NI (1) | NI201900049A (enExample) |
| PE (1) | PE20191145A1 (enExample) |
| PH (1) | PH12019501079A1 (enExample) |
| RU (1) | RU2019115784A (enExample) |
| TN (1) | TN2019000149A1 (enExample) |
| UA (1) | UA125523C2 (enExample) |
| WO (1) | WO2018093949A1 (enExample) |
| ZA (1) | ZA201903099B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10781211B2 (en) | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| CN110290791A (zh) | 2016-11-16 | 2019-09-27 | 灵北拉荷亚研究中心公司 | 药物制剂 |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| EP3541807B1 (en) | 2016-11-16 | 2021-09-29 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| RS64006B1 (sr) | 2017-05-23 | 2023-03-31 | H Lundbeck As | Pirazol magl inhibitori |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| ES2914363T3 (es) | 2017-08-29 | 2022-06-09 | H Lundbeck As | Compuestos espirocíclicos y métodos para su preparación y uso |
| MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
| EP3823723A1 (en) * | 2018-07-19 | 2021-05-26 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| HRP20241201T1 (hr) | 2018-08-13 | 2024-11-22 | F. Hoffmann - La Roche Ag | Novi heterociklički spojevi kao inhibitori monoacilglicerol lipaze |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| WO2023130023A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US12378219B2 (en) | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1003002A (en) | 1910-10-10 | 1911-09-12 | Gustave J Martel | Tire-patching device. |
| MXPA03008109A (es) | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| EP1948630A2 (en) | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| WO2008023720A1 (en) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| CA2716863A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| CA2775703C (en) | 2009-09-29 | 2014-07-08 | Polyone Corporation | Polyester articles having simulated metallic or pearlescent appearance |
| ES2585806T3 (es) | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| US9108937B2 (en) | 2010-03-04 | 2015-08-18 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mGluR2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| SMT202000198T1 (it) * | 2012-01-06 | 2020-07-08 | Scripps Research Inst | Composti di carbammato e metodi di produzione e di utilizzo degli stessi |
| JP2014005245A (ja) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| DK2900669T3 (da) | 2012-09-25 | 2019-11-04 | Hoffmann La Roche | Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme |
| WO2015003002A1 (en) | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| AP2016009496A0 (en) | 2014-04-04 | 2016-10-31 | X-Rx Inc | Substituted spirocydic inhibitors of autotaxin |
| US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US9771341B2 (en) | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| MX2017014344A (es) | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
| UA121775C2 (uk) | 2015-07-31 | 2020-07-27 | Пфайзер Інк. | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| ES2822979T3 (es) | 2015-11-20 | 2021-05-05 | Lundbeck La Jolla Research Center Inc | Derivados de pirazol, procesos para su preparación, y sus usos |
| ES2804580T3 (es) | 2016-03-31 | 2021-02-08 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| US10781211B2 (en) | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
| EP3541807B1 (en) | 2016-11-16 | 2021-09-29 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| CN110290791A (zh) | 2016-11-16 | 2019-09-27 | 灵北拉荷亚研究中心公司 | 药物制剂 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US10350205B2 (en) | 2017-03-13 | 2019-07-16 | Abide Therapeutics, Inc. | Dual MAGL and FAAH inhibitors |
| RS64006B1 (sr) | 2017-05-23 | 2023-03-31 | H Lundbeck As | Pirazol magl inhibitori |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
| ES2914363T3 (es) | 2017-08-29 | 2022-06-09 | H Lundbeck As | Compuestos espirocíclicos y métodos para su preparación y uso |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
-
2017
- 2017-06-16 JO JOP/2019/0107A patent/JOP20190107A1/ar unknown
- 2017-11-15 MX MX2019005773A patent/MX389627B/es unknown
- 2017-11-15 RU RU2019115784A patent/RU2019115784A/ru unknown
- 2017-11-15 CN CN201780083651.3A patent/CN110267962B/zh active Active
- 2017-11-15 CR CR20190239A patent/CR20190239A/es unknown
- 2017-11-15 EA EA201991029A patent/EA038150B1/ru unknown
- 2017-11-15 AU AU2017361253A patent/AU2017361253B2/en not_active Ceased
- 2017-11-15 ES ES17871458T patent/ES2952582T3/es active Active
- 2017-11-15 KR KR1020197017201A patent/KR20190080935A/ko not_active Ceased
- 2017-11-15 EP EP17871458.0A patent/EP3541820B1/en active Active
- 2017-11-15 CA CA3043617A patent/CA3043617A1/en not_active Abandoned
- 2017-11-15 PE PE2019001017A patent/PE20191145A1/es unknown
- 2017-11-15 UA UAA201905617A patent/UA125523C2/uk unknown
- 2017-11-15 BR BR112019009880A patent/BR112019009880A2/pt not_active IP Right Cessation
- 2017-11-15 US US16/349,047 patent/US11059822B2/en active Active
- 2017-11-15 JP JP2019523671A patent/JP7042468B2/ja active Active
- 2017-11-15 TN TNP/2019/000149A patent/TN2019000149A1/en unknown
- 2017-11-15 WO PCT/US2017/061870 patent/WO2018093949A1/en not_active Ceased
- 2017-11-15 MA MA046855A patent/MA46855A/fr unknown
-
2019
- 2019-05-12 IL IL266547A patent/IL266547B/en unknown
- 2019-05-14 CO CONC2019/0004945A patent/CO2019004945A2/es unknown
- 2019-05-14 DO DO2019000118A patent/DOP2019000118A/es unknown
- 2019-05-15 PH PH12019501079A patent/PH12019501079A1/en unknown
- 2019-05-15 EC ECSENADI201934535A patent/ECSP19034535A/es unknown
- 2019-05-16 NI NI201900049A patent/NI201900049A/es unknown
- 2019-05-16 CL CL2019001336A patent/CL2019001336A1/es unknown
- 2019-05-17 ZA ZA2019/03099A patent/ZA201903099B/en unknown
-
2021
- 2021-06-09 US US17/343,227 patent/US11691975B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004945A2 (es) | Inhibidores de la magl | |
| NI202000080A (es) | Inhibidores de magl | |
| CO2019005059A2 (es) | Inhibidores de magl | |
| CO2020001715A2 (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
| CO2019005038A2 (es) | Inhibidores de magl | |
| CO2020001724A2 (es) | Compuestos espirocíclicos y sus métodos de preparación y uso referencia cruzada | |
| MX2022006862A (es) | Inhibidores duales de magl y faah. | |
| CL2019003397A1 (es) | Inhibidores pirazólicos de magl. |